8-K: Sanara MedTech Q2 Revenue Jumps 28%; Explores THP Strategic Alternatives

Sanara MedTech Inc. reported a 28% year-over-year net revenue increase in Q2 2025, reaching $25.8 million, while also announcing a formal process to evaluate strategic alternatives for its Tissue Health Plus (THP) subsidiary.

Summary

• Net revenue for the second quarter of 2025 increased 28% year-over-year to $25.8 million, compared to $20.2 million in Q2 2024.
• Net revenue for the first six months of 2025 increased 27% year-over-year to $49.3 million, compared to $38.7 million in H1 2024.
• The company reported a net loss of $2.0 million in Q2 2025, an improvement from a net loss of $3.5 million in Q2 2024.
• Consolidated net loss for the first six months of 2025 was $5.5 million, compared to a net loss of $5.3 million in H1 2024.
• Adjusted EBITDA for Q2 2025 was $2.7 million, up from $0.6 million in Q2 2024.
• Adjusted EBITDA for H1 2025 was $3.3 million, up from $0.9 million in H1 2024.
• The Sanara Surgical segment generated a net income of $0.5 million in Q2 2025 and a net loss of $0.1 million in H1 2025.
• The Tissue Health Plus (THP) segment generated a net loss of $2.5 million in Q2 2025 and $5.4 million in H1 2025.
• A formal process has been initiated to evaluate strategic alternatives for the Tissue Health Plus, LLC subsidiary, with a strategic advisor engaged.
• Cash and cash equivalents stood at $17.0 million as of June 30, 2025, with long-term debt at $44.2 million.

Sentiment

Score: 7

Explanation: The strong performance of the core Sanara Surgical segment, marked by significant revenue growth and improved profitability, is highly positive. However, the increasing losses and cash burn from the THP segment, leading to a strategic review, introduce uncertainty and temper the overall positive sentiment. The increase in debt and interest expense is also a concern.

Positives

• Net revenue increased significantly by 28% in Q2 2025 to $25.8 million and 27% in H1 2025 to $49.3 million year-over-year.
• Consolidated net loss improved in Q2 2025 to $2.0 million from $3.5 million in Q2 2024.
• Adjusted EBITDA saw substantial growth, reaching $2.7 million in Q2 2025 (from $0.6 million) and $3.3 million in H1 2025 (from $0.9 million).
• The Sanara Surgical segment achieved net income of $0.5 million in Q2 2025, a significant turnaround from a $2.2 million net loss in Q2 2024.
• Sanara Surgical segment's Segment Adjusted EBITDA increased to $4.7 million in Q2 2025 (from $1.4 million) and $7.4 million in H1 2025 (from $2.5 million).
• Gross margin improved to 93% in Q2 2025 from 90% in Q2 2024, driven by increased sales of soft tissue repair products and lower manufacturing costs.
• Cash flow from operating activities turned positive, with $2.7 million generated in Q2 2025 and $0.7 million in H1 2025, compared to cash used in the prior year periods.

Negatives

• Consolidated net loss for the first six months of 2025 worsened slightly to $5.5 million from $5.3 million in H1 2024.
• The Tissue Health Plus (THP) segment continues to incur significant net losses, increasing to $2.5 million in Q2 2025 (from $1.3 million) and $5.4 million in H1 2025 (from $2.6 million).
• THP segment's Segment Adjusted EBITDA also worsened, reaching $(2.1) million in Q2 2025 (from $(0.8) million) and $(4.1) million in H1 2025 (from $(1.6) million), indicating increased cash burn.
• Operating expenses increased by 14% year-over-year in Q2 2025 to $23.9 million, partly due to $1.3 million of additional SG&A in the THP segment.
• Other expense significantly increased to $2.0 million in Q2 2025 (from $0.6 million), primarily due to higher interest expense and fees related to the CRG Term Loan Agreement.
• Long-term debt increased to $44.2 million as of June 30, 2025, from $30.7 million as of December 31, 2024.
• Projected cash investment in the THP strategy for the second half of 2025 is between $5.5 million and $6.5 million, indicating continued significant cash usage for this segment.

Risks

• Uncertainties associated with the development and regulatory approval process for new products.
• Ability to build out the executive team.
• Ability to identify and effectively utilize net proceeds from the CRG Term Loan Agreement to support growth initiatives.
• Extent of product demand, market, and customer acceptance.
• Effect of economic conditions.
• Competition and pricing pressures.
• Ability to consummate and integrate acquisitions.
• Financial performance and increasing cash burn of the Tissue Health Plus (THP) segment, which led to the initiation of a strategic alternatives evaluation process.
• Increased interest expense and fees related to the CRG Term Loan Agreement contributing to higher other expenses.

Future Outlook

The company anticipates continuing its strong sales performance in the Sanara Surgical segment during the second half of 2025, aiming to capitalize on significant untapped growth opportunities for its key products. For the THP segment, a cash investment between $5.5 million and $6.5 million is projected for the second half of 2025, while a formal process to evaluate strategic alternatives is underway to maximize shareholder value.

Management Comments

• "We are pleased to deliver impressive net revenue performance in our Sanara Surgical segment, with 28% growth year-over-year in the second quarter of 2025, fueled by sales of CellerateRX Surgical, BIASURGE, and our portfolio of bone fusion products."
• "This performance was made possible by the Sanara Surgical teams focused execution on our commercial strategy: to continue expanding our network of distributor partners, adding new healthcare facilities to our customer base, and penetrating the existing facilities we serve."
• "In addition to our sales performance, we enhanced our gross margins and realized significant operating expense leverage in our Sanara Surgical segment, generating $0.5 million of net income and $4.7 million of Segment Adjusted EBITDA in the second quarter of 2025, with strong improvements year-over-year."
• "In the second half of 2025, we look forward to continuing our track record of strong sales performance in the Sanara Surgical segment, as we aim to capitalize on the large, untapped growth opportunities for our key products, and continue to execute on our goal to facilitate improved clinical outcomes for clinicians and their patients."
• "In our THP segment, we launched our pilot program with a wound care provider group in late June 2025 and began the first patient encounters under this program. We are pleased with the performance of our THP technology platform during the initial months of this program, while being increasingly mindful of the cash used to support our THP-related initiatives."
• "With this in mind, we have initiated a formal process to evaluate strategic alternatives for our subsidiary Tissue Health Plus, LLC, with the goal of maximizing shareholder value, and have engaged a strategic advisor to assist in this process."
• "We expect to continue our investment in the THP strategy and project our cash investment during the second half of 2025 to be between $5.5 and $6.5 million. In parallel, we are exploring a full range of strategic alternatives for THP, with a focus on identifying and pursuing the best path forward to maximize value for our company and its shareholders."

Industry Context

Sanara MedTech operates within the medical technology sector, specifically focusing on surgical, chronic wound, and skin markets. The strong revenue growth in the Sanara Surgical segment, driven by products like CellerateRX Surgical and BIASURGE, indicates robust demand and successful market penetration in the advanced wound care and surgical tissue repair markets. The decision to evaluate strategic alternatives for the Tissue Health Plus (THP) segment highlights the challenges associated with scaling new, cash-intensive technology platforms, a common hurdle for innovative healthcare solutions. This move aligns with a broader industry trend where companies optimize portfolios by divesting or restructuring underperforming or non-core assets to focus on profitable growth areas and manage cash burn, especially in a capital-intensive sector.

Related Party Transactions

• Accounts receivable related parties of $9,081 as of June 30, 2025.
• Accounts payable related parties of $32,355 as of June 30, 2025.

Stakeholder Impact

• Shareholders: Potential positive impact from strong Sanara Surgical performance and potential value maximization from the THP strategic review. Negative impact from continued consolidated net losses and increased debt.
• Employees: Continued growth in the Sanara Surgical segment may lead to job stability or expansion. Uncertainty for employees in the THP segment due to the strategic review.
• Customers: Continued product development and market penetration aim to improve clinical outcomes in surgical, chronic wound, and skin markets.
• Creditors: Increased long-term debt and interest expense may be a consideration for creditors.

Next Steps

• Continue expanding the network of distributor partners for the Sanara Surgical segment.
• Add new healthcare facilities to the customer base and increase penetration in existing facilities.
• Capitalize on large, untapped growth opportunities for key Sanara Surgical products.
• Continue to execute on the goal to facilitate improved clinical outcomes for clinicians and their patients.
• Continue investment in the THP strategy in the second half of 2025, with projected cash investment between $5.5 million and $6.5 million.
• Proceed with the formal process to evaluate strategic alternatives for the Tissue Health Plus, LLC subsidiary, with assistance from a strategic advisor.
• Host a conference call on August 13, 2025, at 8:00 a.m. Eastern Time to discuss the results for the quarter ended June 30, 2025.

Key Dates

Recommendation

The core Sanara Surgical business demonstrates robust growth and improving profitability, which is a strong positive. However, the significant and increasing losses from the Tissue Health Plus (THP) segment, coupled with the announcement of a formal strategic review for this subsidiary, introduce considerable uncertainty regarding future financial performance and strategic direction. The increase in long-term debt and associated interest expense are also notable concerns. An investor should hold to observe the outcome of the THP strategic review and its implications for the company's overall financial health and long-term strategy before making a more definitive investment decision. The strength of the core business provides a foundation, but the THP situation creates a near-term ceiling on potential upside.

Keywords

Medical Technology, Wound Care, Surgical Products, Tissue Repair, Bone Fusion, Healthcare, SEC Filing, Financial Results, Earnings, Sanara MedTech, SMTI, Adjusted EBITDA, Strategic Alternatives, Tissue Health Plus, CellerateRX Surgical, BIASURGE